SÜSS MicroTec SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SMHN.DE research report →
Price Chart
About the company
SÜSS MicroTec SE, alongside its affiliated companies, specializes in designing, manufacturing, and marketing advanced equipment vital for the production of microelectronic devices, microelectromechanical systems (MEMS), and other associated high-tech applications. The enterprise's operations are segmented into five primary divisions: Photomask Equipment, Lithography, Bonder, Microoptics, and a general 'Others' category. Its product portfolio includes the development, production, and sale of essential tools such as mask aligners, coating and developing systems, UV projection scanners, and laser processing equipment.
- CEO
- Burkhardt Frick
- IPO
- 1999
- Employees
- 1,497
- HQ
- Garching bei München, BV, DE
Get TickerSpark's AI analysis on SMHN.DE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.38B
- P/E
- 49.79
- Fwd P/E
- 40.12
- PEG
- -0.92
- P/S
- 3.14
- P/B
- 4.23
- EV/EBITDA
- 24.21
- Div Yield
- 0.06%
- Gross Margin
- 35.43%
- Op Margin
- 8.69%
- Net Margin
- 6.28%
- ROE
- 8.73%
- ROIC
- 7.12%
Latest fiscal year · YoY change
- Revenue
- $503.18M+12.8%
- Gross Profit
- $179.37M+0.6%
- Op Income
- $60.15M
- Net Income
- $46.11M-58.2%
- EPS
- $2.41-11.1%
- OCF Growth
- -103.0%
- FCF Growth
- -181.0%
- 52W High
- $118.40
- 52W Low
- $24.00
- 50D MA
- $85.39
- 200D MA
- $63.64
- Beta
- 2.28
- RSI (14)
- 40
- Avg Volume
- 103.01K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SUSS MicroTec reported strong first-half order intake and a record backlog, but kept full-year guidance unchanged as 2026 remains a transition year with higher second-half sales expected.· August 6, 2026
- H1 order intake reached EUR 410 million, including EUR 260 million in Q2, driven by broad demand and a EUR 115 million coater order from Taiwan.
- The order book hit a record EUR 473.7 million, with about EUR 240 million expected to convert into H2 2026 sales and around EUR 220 million scheduled for 2027.
- H1 revenue was EUR 202.8 million, with Q2 sales of EUR 160.2 million after a weaker Q1.
- Gross profit margin was 37.2%, ahead of the 35% to 37% guidance range, while Q2 EBIT margin improved to 9% from 4.3% in Q1.
- Management confirmed full-year guidance: sales of EUR 425 million to EUR 485 million, gross margin of 35% to 37%, and EBIT margin of 8% to 10%.
For H1 2026, revenue was EUR 202.8 million, with Q2 sales at EUR 160.2 million. Order intake totaled EUR 410 million in H1 and EUR 260 million in Q2, helped by a EUR 115 million coater order. Gross profit margin was 37.2% for H1, slightly ahead of the 35% to 37% guidance corridor, while Q2 EBIT margin was 9% versus 4.3% in Q1; management also said H1 EBIT margin was still below the full-year target range. Free cash flow was positive at EUR 16.4 million, and cash and cash equivalents rose to EUR 112.3 million. Full-year guidance was confirmed at revenue of EUR 425 million to EUR 485 million, gross margin of 35% to 37%, and EBIT margin of 8% to 10%.
Burkhardt Frick framed 2026 as a transition year, saying Q1 was the low point and Q2 showed the expected improvement. He emphasized strong demand for existing product generations, broad order momentum across product lines, and improving visibility into 2027 from the record backlog. He was confident on execution but repeatedly cautioned that the window for converting new orders into 2026 revenue is closing.
Cornelia Ballwißer said H1 sales of EUR 202.8 million were in line with expectations, with Q2 sales of EUR 160.2 million showing the expected recovery. Gross profit margin was 37.2%, slightly below the prior-year level and affected by product/customer mix plus a EUR 2.1 million one-time charge tied to a withdrawn product; operating expenses rose only EUR 0.3 million, including R&D up EUR 1.6 million to EUR 24.9 million. She highlighted positive free cash flow of EUR 16.4 million, cash of EUR 112.3 million, and lower CapEx versus last year, while reiterating the EBIT margin target of 8% to 10%.
Analysts focused on whether the large Q2 coater order distorted the underlying demand run rate and whether H2 order intake could stay near H1 levels; management declined to guide order intake, saying spikes from large orders make it too hard to predict. They also pressed on whether 2026 sales could still benefit from late-quarter orders, and management said only some shorter-lead-time tools could still fit into the year, while bigger tools are effectively beyond the 2026 window. Questions on margin sustainability, temporary bonders, and new products drew responses that the company is keeping R&D and launch spending high, sees no major near-term momentum yet from one Korean customer in temporary bonding, and expects new-product orders to build gradually through 2027.
The positive case from this call is that demand appears broad-based and durable, not just a one-off spike from the EUR 115 million order. Management said existing products are driving momentum, the backlog is at an all-time high, and roughly EUR 220 million is already scheduled for 2027, which improves visibility beyond this year. They also pointed to improving gross margin, better Q2 EBIT leverage, and several upcoming product launches and the new Karlsruhe application/R&D center as supports for longer-term growth.
The main risk is that 2026 upside is limited because much of the recent order book appears to be pushed into 2027, and management said the window for additional 2026-convertible orders is closing. H1 revenue still lagged the prior year, EBIT margin was below target after six months, and management said R&D and other strategic spending will stay high, limiting near-term operating leverage. There are also product-specific uncertainties, including weaker Photomask Solutions sales after slow late-2025 ordering and no clear near-term visibility on some temporary bonding demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.3%
- Shares Outstanding
- 19.12M
- Float Shares
- 18.60M
Held by 188 ETFs
Biggest fund positions in SMHN.DE by dollar value.
Our SMHN.DE coverage
Recent articles, reports, and earnings notes.
No research on SMHN.DE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SMHN.DE report →